Drug profile · INN
perampanel
FYCOMPA
perampanel (FYCOMPA) is a glutamate receptor ionotropic ampa antagonist. Associated with Eisai Co.,. Route of administration: oral. Current US regulatory status: approved.
Drug details — perampanel
- US status
- approved
- Class
- Nervous system (N03)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
perampanel (FYCOMPA) is a glutamate receptor ionotropic ampa antagonist. Associated with Eisai Co.,. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Glutamate receptor ionotropic AMPA antagonist
Primary target: Glutamate receptor ionotropic AMPA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is perampanel?
perampanel (FYCOMPA) is a glutamate receptor ionotropic ampa antagonist. Associated with Eisai Co.,. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for perampanel?
FYCOMPA is a marketed brand name for perampanel. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of perampanel?
perampanel has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.